Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-04-19

Opinion for Celgene Corp (CELG-Q)

Signal Price Bias Subject Owned
TOP PICK $122.920 UNKNOWN LARGE CAP GROWTH & DIVIDENDS Yes

One of the surest growth stocks out there. They have a product called Revlimid which treats a whole series of blood cancers. The one they have right now is multiple myeloma, and it prolongs people’s lives substantially. They are going to grow revenue 25% over the next 4 years. It is selling at 18X. Thinks it gets close to $200 in the next couple of years. (Analysts’ price target is $143.)

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group

No Comments.


You must be logged in to comment.